William Blair Issues Pessimistic Estimate for NMRA Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Stock analysts at William Blair reduced their FY2024 earnings per share estimates for shares of Neumora Therapeutics in a research note issued on Tuesday, November 12th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($1.63) per share for the year, down from their previous estimate of ($1.48). The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.48) per share. William Blair also issued estimates for Neumora Therapeutics’ Q4 2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($1.94) EPS.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period last year, the firm earned ($1.14) EPS.

Several other brokerages have also recently commented on NMRA. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Neumora Therapeutics in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday. JPMorgan Chase & Co. cut Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $29.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $21.67.

Neumora Therapeutics Stock Performance

NASDAQ NMRA opened at $10.84 on Friday. The firm’s 50 day moving average price is $13.10 and its two-hundred day moving average price is $11.44. Neumora Therapeutics has a twelve month low of $8.33 and a twelve month high of $21.00. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -5.80 and a beta of 3.92.

Institutional Trading of Neumora Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in NMRA. Amalgamated Bank increased its holdings in shares of Neumora Therapeutics by 472.8% during the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after acquiring an additional 2,402 shares during the last quarter. Quarry LP acquired a new position in Neumora Therapeutics during the second quarter valued at approximately $98,000. SkyOak Wealth LLC acquired a new position in Neumora Therapeutics during the second quarter valued at approximately $147,000. Principal Financial Group Inc. acquired a new stake in shares of Neumora Therapeutics in the second quarter worth $166,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Neumora Therapeutics in the third quarter worth $175,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Insider Buying and Selling at Neumora Therapeutics

In related news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the sale, the director now owns 20,100 shares of the company’s stock, valued at approximately $342,303. The trade was a 41.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joshua Pinto sold 28,496 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $11.63, for a total transaction of $331,408.48. Following the transaction, the chief financial officer now directly owns 210,469 shares in the company, valued at $2,447,754.47. The trade was a 11.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 110,538 shares of company stock worth $1,390,513 over the last 90 days. 26.40% of the stock is currently owned by corporate insiders.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.